LON:GSK GSK (GSK) Share Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free GSK Stock Alerts GBX 1,708.60 +3.40 (+0.20%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range 1,699.21▼ 1,71350-Day Range 1,521.20▼ 1,711.2052-Week Range 1,302.60▼ 1,719.80Volume6.64 million shsAverage Volume7.31 million shsMarket Capitalization£69.37 billionP/E Ratio1,423.83Dividend Yield3.75%Price TargetGBX 1,658.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability Get GSK alerts: Email Address GSK MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside2.9% DownsideGBX 1,658.75 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-1.56Upright™ Environmental ScoreNews Sentiment0.74Based on 4 Articles This WeekInsider TradingSelling Shares£231.78 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.03 out of 5 stars 1.2 Analyst's Opinion Consensus RatingGSK has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,658.75, GSK has a forecasted downside of 2.9% from its current price of GBX 1,708.60.Amount of Analyst CoverageGSK has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GSK. Previous Next 1.7 Dividend Strength Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 3.89%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGSK has received a 66.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HIV medication", "Shingles vaccines", "Mouthwash", "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Clinical research services for the respiratory system" products. See details.Environmental SustainabilityThe Environmental Impact score for GSK is -1.56. Previous Next 2.6 News and Social Media Coverage News SentimentGSK has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for GSK this week, compared to 7 articles on an average week.Search Interest61 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added GSK to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GSK insiders have sold 638.57% more of their company's stock than they have bought. Specifically, they have bought £313,814.84 in company stock and sold £2,317,751.36 in company stock.Percentage Held by InsidersOnly 2.25% of the stock of GSK is held by insiders.Percentage Held by Institutions45.11% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 1,423.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 141.99.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 1,423.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 220.56.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.10. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 5.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About GSK Stock (LON:GSK)GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Read More GSK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GSK Stock News HeadlinesMarch 23, 2024 | insidertrades.comInsider Buying: GSK plc (LON:GSK) Insider Buys 434 Shares of StockMarch 23, 2024 | americanbankingnews.comGSK plc (LON:GSK) Insider Urs Rohner Buys 434 Shares of StockMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 21, 2024 | benzinga.comSenator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per MonthMarch 20, 2024 | markets.businessinsider.comSosei Regains Full Ownership From GSK Of Clinic-Ready GPR35 Agonist For Inflammatory Bowel DiseaseMarch 20, 2024 | reuters.comGSK to cap out-of-pocket inhaler costs in USMarch 20, 2024 | americanbankingnews.comGSK (LON:GSK) Stock Price Passes Above Two Hundred Day Moving Average of $1,518.97March 20, 2024 | americanbankingnews.comGSK plc (LON:GSK) Given Average Recommendation of "Hold" by AnalystsMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 18, 2024 | msn.comGSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial CancerMarch 18, 2024 | lse.co.ukGSK says Jemperli combination gets good results for endometrial cancerMarch 18, 2024 | marketwatch.comGSK's Endometrial Cancer Treatment Study Shows Combination PotentialMarch 9, 2024 | finance.yahoo.comGSK Mar 2024 41.000 callMarch 9, 2024 | finance.yahoo.comGSK Mar 2024 34.000 putMarch 7, 2024 | msn.comGSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage StudyMarch 7, 2024 | msn.comGSK’s Blenrep combo therapy meets key goal in multiple myeloma trialMarch 7, 2024 | msn.comGSK's blood cancer drug meets main goal in late-stage trial; analysts tout comebackMarch 6, 2024 | es-us.finanzas.yahoo.comCORRECTED-GSK's new HIV drug formula could support longer dosing intervals (March 4)March 6, 2024 | msn.comWHO warns of growing resistance to GSK's HIV drugMarch 4, 2024 | msn.comNew HIV drug Cabotegravir that can be taken as little as three times a year boosts GSKMarch 4, 2024 | investing.comGuggenheim lifts GSK to Buy on improved growth outlookMarch 4, 2024 | theglobeandmail.comHow DEI is helping GSK get ahead of diseaseMarch 1, 2024 | theguardian.comGSK boss’s annual pay package jumps 50% to £12.7mFebruary 26, 2024 | finance.yahoo.comGSK drug meets goal in late-stage gonorrhea studyFebruary 26, 2024 | msn.comGSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted InfectionFebruary 26, 2024 | thetimes.co.ukGSK’s new gonorrhoea pill ‘as good as injected antibiotic’February 26, 2024 | msn.comGSK’s gonorrhoea drug achieves efficacy goal in pivotal trialSee More Headlines Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2020Ex-Dividend for 1/11 Dividend11/16/2023Dividend Payable1/11/2024Ex-Dividend for 4/11 Dividend2/22/2024Today3/28/2024Dividend Payable4/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolLON:GSK CUSIPN/A CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees70,212Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,658.75 High Stock Price TargetGBX 1,950 Low Stock Price TargetGBX 1,300 Potential Upside/Downside-2.9%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 1.20 Trailing P/E Ratio1,423.83 Forward P/E Ratio10.71 P/E Growth1.1Net Income£4.93 billion Net Margins16.25% Pretax MarginN/A Return on Equity46.38% Return on Assets8.81% Debt Debt-to-Equity Ratio140.82 Current Ratio0.88 Quick Ratio0.73 Sales & Book Value Annual Sales£30.33 billion Price / Sales2.29 Cash FlowGBX 209.76 per share Price / Cash Flow8.15 Book ValueGBX 329 per share Price / Book5.19Miscellaneous Outstanding Shares4,060,000,000Free FloatN/AMarket Cap£69.37 billion OptionableNot Optionable Beta0.26 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Emma Natasha Walmsley (Age 55)CEO & Director Comp: $5.39MMs. Julie Belita Brown (Age 62)CFO & Executive Director Comp: $5.14MMs. Shobie Ramakrishnan (Age 53)Chief Digital & Technology Officer Mr. Tony WoodChief Scientific Officer and Head of R&DMs. Sarah Elton-FarrHead of Investor RelationsMr. James FordSenior VP & Group General Counsel of Legal & ComplianceMs. Sally JacksonSenior Vice President of Global Communications & CEO OfficeMr. David Simon Redfern BSc (Hons) (Age 58)CA, President of Corporate Development Ms. Diana ConradChief People OfficerMr. Philip C. ThomsonPresident of Global AffairsMore ExecutivesKey CompetitorsAstraZenecaLON:AZNHaleonLON:HLNDechra PharmaceuticalsLON:DPHSmith & NephewLON:SNConvaTec GroupLON:CTECView All CompetitorsInsidersUrs RohnerBought 434 shares on 3/20/2024Total: £721,308.00 ($1,662.00/share)Emma WalmsleySold 139,792 sharesTotal: £231.78 M ($1,658.00/share)Emma WalmsleyBought 8 shares on 2/9/2024Total: £13,296.00 ($1,662.00/share)Julie BrownBought 19,360 shares on 2/1/2024Total: £30.65 M ($1,583.00/share)Urs RohnerBought 478 shares on 12/20/2023Total: £693,100.00 ($1,450.00/share)View All Insider Transactions Should I Buy GSK Stock? GSK Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of GSK was last updated on Monday, March 25, 2024 at 11:49 AM. Pros Here are some ways that investors could benefit from investing in GSK plc: GSK plc has shown consistent growth in revenue and earnings, indicating financial stability and potential for returns. Recent analyst ratings and target prices suggest a positive outlook for the stock, with potential upside for investors. The company's stock price has been performing well, showing resilience and potential for capital appreciation. GSK plc has a diverse portfolio of pharmaceutical products, reducing risk associated with dependency on a single product. Strong institutional investor interest in GSK plc indicates confidence in the company's future performance. Cons Investors should be bearish about investing in GSK plc for these reasons: GSK plc's debt-to-equity ratio is relatively high, which may pose risks in terms of financial leverage and interest payments. The company's P/E ratio is high, suggesting the stock may be overvalued compared to its earnings potential. GSK plc's beta indicates lower volatility compared to the market, potentially limiting short-term trading opportunities for investors. The current ratio of GSK plc is below 1, indicating potential liquidity challenges in meeting short-term obligations. Market competition and regulatory challenges in the pharmaceutical industry could impact GSK plc's growth prospects and market share. GSK Stock Analysis - Frequently Asked Questions Should I buy or sell GSK stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares. View GSK analyst ratings or view top-rated stocks. What is GSK's stock price target for 2024? 7 brokers have issued 12 month price objectives for GSK's stock. Their GSK share price targets range from GBX 1,300 to GBX 1,950. On average, they expect the company's share price to reach GBX 1,658.75 in the next twelve months. This suggests that the stock has a possible downside of 2.9%. View analysts price targets for GSK or view top-rated stocks among Wall Street analysts. How have GSK shares performed in 2024? GSK's stock was trading at GBX 1,450.20 on January 1st, 2024. Since then, GSK shares have increased by 17.8% and is now trading at GBX 1,708.60. View the best growth stocks for 2024 here. How were GSK's earnings last quarter? GSK plc (LON:GSK) released its earnings results on Wednesday, July, 29th. The company reported $56.90 earnings per share (EPS) for the quarter. GSK had a trailing twelve-month return on equity of 46.38% and a net margin of 16.25%. How often does GSK pay dividends? What is the dividend yield for GSK? GSK declared a dividend on Wednesday, January 31st. Investors of record on Thursday, February 22nd will be paid a dividend of GBX 16 per share on Thursday, April 11th. This represents a dividend yield of 1.04%. The ex-dividend date of this dividend is Thursday, February 22nd. This is an increase from the stock's previous dividend of GBX 14. The official announcement can be viewed at this link. Read our dividend analysis for GSK. Is GSK a good dividend stock? GSK (LON:GSK) pays an annual dividend of GBX 64 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for GSK. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD). How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:GSK) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.